Compliance Blog

The EU Pharmaceutical Package

Written by Admin | Nov 18, 2026, 1:46:27 PM

Pharmaceutical law in transition: What is the EU Pharma Package and when does it apply?

The EU Pharma Package, also called the pharmaceutical package, is the first comprehensive overhaul of the European legal regulations for medicinal products since 2004 and is intended to fundamentally renew the legal framework for medicinal products for the first time in more than 20 years. The changes are intended to adapt the regulations on medicinal products to today’s healthcare supply needs. The primary focus here is on ensuring supply security for patients. At the same time, competition and innovation are to be strengthened. Targeted incentives are intended to promote investments in new antimicrobial agents, in medicines for rare diseases and in paediatric medicines, where gaps have frequently existed to date for economic reasons.

The key question for your planning is: From when do the new regulations apply? In short: The package has been politically agreed and adopted by the Council of the EU. Approval by the European Parliament and publication in the Official Journal are still pending, and the package will not become effective before then. The new regulation is expected to apply 24 months after it enters into force. Publication in the Official Journal is still expected this year. This likely means an application start between late 2028 and early 2029, unless otherwise specified in the standards.

What is the EU Pharma Package?

The package consists of two legal acts:

  • The new directive (Union code for medicinal products for human use) replaces the previous Directives 2001/83/EC and 2009/35/EC. The Member States must transpose it into national law within the period set therein before it applies there.

  • The new regulation revises the centralised authorisation procedure and the European Medicines Agency (EMA). It replaces, among other things, Regulation (EC) No 726/2004 and applies directly in all Member States from its application date, without the need for a transposition act.

 

Why is pharmaceutical law being revised?

The European Commission presented the drafts in April 2023. The aim is better access to medicines, more reliable supply and a more competitive pharmaceutical base in Europe. Experiences with the COVID pandemic and recurring supply shortages also play a role. In addition, the competitiveness of the pharmaceutical industry is to be strengthened. To this end, the regulatory burden is being reduced and supply security expanded to prevent and manage shortages.

Where does the process stand today?

The Council of the EU adopted the EU Pharma Package on 28 September 2026. The preceding political agreement between the Council and the European Parliament was reached in December 2025. The final texts were published in September 2026. What remains outstanding is the formal approval of the European Parliament and publication in the Official Journal of the EU, which are expected for late November or early December 2026.
 
Step Date
Status
European Commission proposal  April 2023  Completed 
Political agreement between Council and Parliament 11 December 2025 Completed
Council position at first reading  28 September 2026 
Completed 
Vote in the European Parliament 
Announced for autumn 2026
Currently pending 
Publication in the Official Journal of the EU 
Expected Nov. to Dec. 2026 
Currently pending 

 


When will the EU Pharma Package become relevant?

The timeline for entry into force and application is clearly set out in the package. The regulation is expected to enter into force on the 20th day after its publication in the Official Journal of the European Union; most provisions will likely become applicable 24 months thereafter, unless otherwise specified. If publication takes place at the end of 2026, as currently announced, this would result in application in the fourth quarter of 2028. Individual provisions will likely take effect earlier, and both legal acts also contain transitional provisions that must still be observed. In addition, there are numerous implementing and delegated acts of the Commission. This results in a staggered implementation process, in which particular attention must be paid to the respective deadlines.


What applies until application?

Until the application date, the existing law remains in force. Ongoing authorisations and obligations continue unchanged. An immediate changeover is therefore not required. However, it is worthwhile to follow developments early and clarify responsibilities.


Conclusion

The EU Pharma Package fundamentally changes pharmaceutical law in the EU. Most new requirements are likely to become effective between the end of 2028 and the beginning of 2029. Those who know the timeline and monitor developments can approach the transition without time pressure.